Treatment of hepatic encephalopathy and liver cirrhosis

US10166202B2 · kind B2 · utility

Assignees

• YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. · IL
• HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. · IL
• ARISTOTLE UNIVERSITY OF THESSALONIKI-ELKE · GR

Inventors

• Elliot Berry · Jerusalem, IL
• Yosefa Avraham · Jerusalem, IL
• Raphael Mechoulam · Jerusalem, IL
• Yaron Ilan · Kfar Tavor, IL
• Yossi Dagon · Cambridge, US
• Iddo Magen · Modiin-Maccabim-Reut, IL
• Nicholas Grigoriadis · Egio, GR
• Theofilos Poutachidis · Neos Skopos, GR

Key dates

• Filing date: Jun 16, 2011
• Grant date: Jan 1, 2019
• Expiry date: Jun 16, 2031

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The compounds D9-tetrahydrocannabinol (THC), cannabidiol (CBD) and capsaicin are useful for prevention, treatment, or both, of hepatic encephalopathy. The compounds capsaicin, 2-arachidonoylglycerol (2-AG), HU-308 and cannabidiol are useful for prevention, treatment, or both, of liver cirrhosis.